Saudi Central Bank Has $2.29 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Saudi Central Bank grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 89.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 11,879 shares of the medical research company’s stock after acquiring an additional 5,593 shares during the period. Saudi Central Bank’s holdings in IQVIA were worth $2,295,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Financial Freedom LLC acquired a new position in IQVIA in the first quarter valued at about $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA during the first quarter worth about $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at about $27,000. Compass Financial Management LLC acquired a new stake in IQVIA during the 2nd quarter worth approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new position in IQVIA in the fourth quarter valued at approximately $27,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IQV. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. increased their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Stifel Nicolaus upped their price objective on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $243.62.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 15,581 shares of company stock worth $3,796,021 over the last three months. Company insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $267.34 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80. The company’s fifty day simple moving average is $232.02 and its 200-day simple moving average is $193.57. The firm has a market cap of $44.00 billion, a PE ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the business earned $2.81 EPS. The company’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.